v3.26.1
FAIR VALUE MEASUREMENTS (Tables)
3 Months Ended
Mar. 31, 2026
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured on a Recurring Basis
The following represents assets and liabilities measured at fair value on a recurring basis by the Company (in thousands):
March 31, 2026Fair ValueLevel 1Level 2Level 3
Assets:
Money market funds$15,423 $15,423 $— $— 
Investment in iECURE744 — — 744 
Imugene Marketable Securities1,814 1,814 — — 
$17,981 $17,237 $— $744 
Liabilities:
Final payment fee$211 $— $211 $— 
Warrant liability22,802 — — 22,802 
$23,013 $— $211 $22,802 
December 31, 2025Fair ValueLevel 1Level 2Level 3
Assets:
Money market funds$15,286 $15,286 $— $— 
Investment in iECURE744 — — 744 
Imugene Marketable Securities4,762 4,762 — — 
$20,792 $20,048 $— $744 
Liabilities:
Final payment fee$208 $— $208 $— 
Warrant Liability15,695 — — 15,695 
$15,903 $— $208 $15,695 
Summary of Financial Assets Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs
The following represents a reconciliation of assets measured and carried at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) for the three months ended March 31, 2026 (in thousands). The warrant reconciliation is disclosed in Note 11, Warrants:
Investment in iECURE
Balance December 31, 2025$744 
(Loss) gain from changes in fair value included in earnings— 
Balance March 31, 2026$744